Tirzepatide can cause side effects, most commonly digestive symptoms such as nausea, diarrhea, vomiting, constipation, abdominal pain, and indigestion. Other reported effects include injection-site reactions, fatigue, belching, hair loss, allergic reactions, and reflux. Many gastrointestinal effects occur during treatment initiation or clinician-directed dose escalation and may decrease over time, but severe, persistent, or worsening symptoms should be medically evaluated.
At Drip Lounge, Tirzepatide care is approached as a medically supervised weight-management pathway rather than simply access to an injection. If you are considering treatment, you can learn more about the provider-guided Tirzepatide weight-management program.
The important question is not simply, "Does Tirzepatide have side effects?" Almost every prescription medication does. The more useful questions are:
- Which Tirzepatide side effects are common?
- Which symptoms should you discuss with your clinician?
- Which symptoms may require urgent evaluation?
- Does your medical history increase certain risks?
- What should your care team know before you start treatment?
This guide answers those questions using current prescribing information and clinical safety data.
Written by: Drip Lounge Editorial Team
Medically reviewed by: Megan Nickerson, DNP · Last medically reviewed: August 14, 2026
Last regulatory-label review: August 14, 2026
Medical disclaimer: This article provides general educational information. It is not personal medical advice, diagnosis, emergency guidance, or a recommendation to start, stop, skip, or change Tirzepatide. Medication decisions should be made with your prescribing clinician.
Tirzepatide Side Effects at a Glance
| Question | Short Answer |
|---|---|
| Most common side effects | Nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion and other GI symptoms |
| Other common reactions | Injection-site reactions, fatigue, hypersensitivity reactions, belching, hair loss and reflux |
| When do GI symptoms commonly occur? | Frequently during initiation or clinician-directed dose escalation |
| Can serious reactions occur? | Yes, although they are less common |
| Major safety topics | Thyroid C-cell tumor boxed warning, severe GI reactions, pancreatitis, gallbladder disease, dehydration-related kidney injury, hypersensitivity, hypoglycemia in certain patients, diabetic retinopathy and aspiration risk around anesthesia |
| Should you adjust the medication yourself? | No |
| Is medical follow-up important? | Yes |
In pooled SURMOUNT-1 and SURMOUNT-2 data, gastrointestinal adverse reactions occurred in about 56% of Zepbound-treated adults versus 30% receiving placebo. Nausea affected roughly 25%–29% of participants depending on dose, diarrhea 19%–23%, vomiting 8%–13%, and constipation 11%–17%.
What Is Tirzepatide?
Tirzepatide is the active ingredient in two FDA-approved prescription medications: Zepbound and Mounjaro.
Zepbound is approved for chronic weight management in eligible adults with obesity or overweight plus at least one weight-related condition, as well as moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro contains the same active ingredient but has a different FDA-labeled context involving type 2 diabetes.
Tirzepatide activates both GIP and GLP-1 receptors, which influence appetite, food intake, glucose regulation, digestion, and metabolic signaling. Because those pathways affect the digestive system, gastrointestinal symptoms are among the most frequent adverse reactions.
If you want the broader treatment overview before focusing on safety, visit the Tirzepatide weight-management program, or read our explainer on what Tirzepatide is and how it works.
Readers who are new to peptide-based medications may also want to start with our guide to what peptide therapy is, the different types, and how safety varies.
What Are the Most Common Tirzepatide Side Effects?
The most common Tirzepatide side effects are primarily gastrointestinal. Current Zepbound safety data identify:
- nausea;
- diarrhea;
- vomiting;
- constipation;
- abdominal pain;
- dyspepsia or indigestion;
- injection-site reactions;
- fatigue;
- hypersensitivity reactions;
- belching;
- hair loss;
- gastroesophageal reflux disease;
- flatulence;
- abdominal bloating;
- dizziness;
- and, less commonly, hypotension.
Common Side Effects by Frequency
Pooled clinical-trial data provide useful context:
| Adverse Reaction | Zepbound 5 mg | Zepbound 10 mg | Zepbound 15 mg | Placebo |
|---|---|---|---|---|
| Nausea | 25% | 29% | 28% | 8% |
| Diarrhea | 19% | 21% | 23% | 8% |
| Vomiting | 8% | 11% | 13% | 2% |
| Constipation | 17% | 14% | 11% | 5% |
| Abdominal pain | 9% | 9% | 10% | 5% |
| Indigestion | 9% | 9% | 10% | 4% |
| Injection-site reaction | 6% | 8% | 8% | 2% |
| Fatigue | 5% | 6% | 7% | 3% |
| Hair loss | 5% | 4% | 5% | 1% |
| Reflux | 4% | 4% | 5% | 2% |
These figures come from pooled weight-management studies and describe study populations—not what any one person is guaranteed to experience.
Tirzepatide Nausea
Nausea is among the most frequently reported Tirzepatide side effects. In pooled Zepbound trials, approximately one-quarter to just under one-third of participants reported nausea, depending on the treatment group.
Some people may notice nausea primarily during the early stages of treatment or after clinician-directed dose increases. Lilly reports that most nausea, vomiting, and diarrhea occurred during dose escalation and generally decreased over time.
That does not mean persistent nausea should simply be ignored. Contact your clinician when nausea:
- persists;
- becomes severe;
- makes normal eating difficult;
- prevents adequate fluid intake;
- is accompanied by repeated vomiting;
- or is associated with significant abdominal pain.
Do not independently skip, increase, decrease, or otherwise modify prescription treatment based on online advice.
Can Tirzepatide Cause Diarrhea?
Yes. Diarrhea is another common adverse reaction. Clinical-trial rates ranged from approximately 19% to 23% across Zepbound weight-management doses, compared with 8% among placebo participants.
The main safety concern with persistent diarrhea is not simply discomfort. Significant fluid loss can contribute to dehydration, which may in turn affect kidney function.
Contact your clinical team if diarrhea becomes prolonged, severe, or difficult to manage, particularly if you develop dizziness, unusual thirst, dark urine, faintness, or difficulty maintaining adequate fluid intake.
Can Tirzepatide Cause Vomiting?
Vomiting occurred in approximately 8% to 13% of Zepbound-treated participants in pooled weight-management trials, compared with about 2% of placebo participants.
Occasional vomiting and repeated vomiting are not the same safety situation. Repeated vomiting can lead to:
- dehydration;
- electrolyte disturbances;
- inability to eat or drink;
- worsening weakness;
- and, in susceptible patients, kidney complications.
If you cannot keep fluids down or vomiting is severe or persistent, contact a medical professional promptly.
Tirzepatide and Constipation
Constipation is also common. Rates in pooled clinical trials ranged from roughly 11% to 17%, compared with approximately 5% for placebo.
Constipation can range from mild changes in bowel habits to significant discomfort. Your clinician should know if constipation becomes:
- persistent;
- painful;
- associated with significant abdominal swelling;
- accompanied by vomiting;
- or substantially different from your normal bowel pattern.
Online information cannot determine whether a bowel symptom is an expected treatment effect or a separate medical problem.
Abdominal Pain, Indigestion, and Reflux
Abdominal discomfort, dyspepsia, belching, bloating, and gastroesophageal reflux are all reported with Tirzepatide. In the pooled clinical-trial data:
- abdominal pain occurred in roughly 9%–10%;
- indigestion in approximately 9%–10%;
- reflux in about 4%–5%;
- belching in approximately 4%–5%.
The key distinction is severity and persistence. Mild temporary indigestion and severe persistent abdominal pain should never be treated as equivalent.
Severe or persistent abdominal pain is especially important because it can overlap with symptoms of more serious conditions such as pancreatitis or gallbladder disease.
Can Tirzepatide Cause Hair Loss?
Hair loss is listed among common Zepbound adverse reactions. In pooled weight-management trials, hair loss occurred in approximately 4%–5% of Zepbound participants versus 1% receiving placebo.
However, hair loss during weight reduction can have multiple possible contributors. Changes in nutrition, rapid weight loss, protein intake, iron status, thyroid health, stress, underlying hair conditions, hormonal changes, and medications may all be relevant.
That is why hair loss during treatment should not automatically be attributed to one cause. A clinician can help determine whether further assessment is appropriate.
Tirzepatide Injection-Site Reactions
Injection-site reactions occurred in approximately 6%–8% of Zepbound participants in pooled studies. Possible local symptoms can include:
- redness;
- irritation;
- tenderness;
- itching;
- swelling;
- or localized discomfort.
Persistent, worsening, unusually painful, spreading, or otherwise concerning reactions should be discussed with your care team. Signs that could suggest infection or a more serious allergic reaction require more urgent evaluation.
When Should You Call Your Clinician?
Contact your prescribing clinician promptly if you experience:
- persistent nausea;
- repeated vomiting;
- prolonged diarrhea;
- severe constipation;
- difficulty eating or drinking;
- signs of dehydration;
- new or worsening abdominal pain;
- persistent reflux or indigestion;
- significant dizziness or faintness;
- new or changing vision symptoms if you have diabetes;
- concerning injection-site reactions;
- or symptoms that are interfering with normal daily activities.
The goal is not to label every unpleasant sensation as dangerous. It is to avoid dismissing a clinically important symptom as "just a side effect."
When Can Tirzepatide Symptoms Require Urgent Medical Attention?
Seek urgent medical evaluation for severe or rapidly worsening symptoms, particularly:
- trouble breathing;
- swelling of the face, lips, tongue, or throat;
- severe persistent abdominal pain;
- abdominal pain that radiates toward the back;
- repeated vomiting with inability to maintain fluids;
- significant dehydration;
- fainting;
- or another severe, sudden medical symptom.
Current Zepbound safety information specifically highlights serious hypersensitivity reactions, acute pancreatitis, severe gastrointestinal reactions, gallbladder disease, and dehydration-related kidney injury as important clinical risks.
If you believe you are experiencing a medical emergency, use emergency medical services rather than waiting for a routine clinic response.
Serious Tirzepatide Warnings and Precautions
The common side effects receive most of the attention online, but a safety-focused Tirzepatide guide also needs to clearly explain the less common but more important warnings.
Boxed Warning: Thyroid C-Cell Tumors
Zepbound carries an FDA boxed warning regarding thyroid C-cell tumors.
Tirzepatide caused dose- and treatment-duration-dependent thyroid C-cell tumors in rats at clinically relevant exposures. It is currently unknown whether Tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans.
Zepbound is contraindicated in people with:
- a personal history of medullary thyroid carcinoma;
- a family history of medullary thyroid carcinoma;
- or Multiple Endocrine Neoplasia syndrome type 2.
Patients should discuss relevant personal and family medical history before beginning treatment.
The boxed warning should not be rewritten online as "Tirzepatide causes thyroid cancer." That is not what current evidence establishes. The correct distinction is that tumors occurred in rats and the relevance to humans remains unknown.
Severe Gastrointestinal Reactions
Tirzepatide can cause gastrointestinal reactions that are sometimes severe. Across pooled Zepbound studies, severe GI adverse reactions were reported in approximately:
- 1.7% at 5 mg;
- 2.5% at 10 mg;
- 3.1% at 15 mg;
- versus 1.0% with placebo.
Zepbound is not recommended in patients with severe gastroparesis. People with significant gastrointestinal disease should make sure that history is discussed before treatment.
Tirzepatide and Pancreatitis
Acute pancreatitis has been observed in patients treated with GLP-1 receptor agonists and with Zepbound. Current prescribing information notes that symptoms may include persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting.
Pancreatitis cannot be diagnosed based on symptoms listed in a blog. But severe persistent abdominal pain is a reason for prompt clinical assessment rather than waiting to see whether it disappears.
Tirzepatide and Gallbladder Problems
Acute gallbladder disease is another labeled safety concern. In pooled SURMOUNT-1 and SURMOUNT-2 data:
- gallstones were reported in 1.1% of Zepbound participants and 1.0% of placebo;
- cholecystitis occurred in 0.7% versus 0.2%;
- cholecystectomy occurred in 0.2% of Zepbound participants and none receiving placebo.
Gallbladder events were associated with weight reduction in the trials. Potential symptoms such as significant upper abdominal pain, fever, vomiting, or jaundice deserve medical evaluation.
Kidney Injury and Dehydration
Tirzepatide's gastrointestinal side effects can sometimes cause enough fluid loss to create a second problem.
FDA-approved safety information describes postmarketing cases of acute kidney injury, including cases requiring dialysis, in patients receiving Zepbound or GLP-1 receptor agonists. Most occurred in people experiencing GI symptoms that led to dehydration, such as vomiting, nausea, or diarrhea.
This is why persistent vomiting and diarrhea should not automatically be treated as minor inconveniences. Your clinician may need to assess hydration and kidney function when clinically appropriate.
Hypoglycemia and Diabetes Medications
Tirzepatide lowers blood glucose. Low blood sugar can occur, and risk may be higher when Tirzepatide is combined with medications such as insulin or sulfonylureas.
Patients using diabetes medication should make sure their prescribing clinician knows exactly which medications they take. Medication combinations should be managed professionally rather than adjusted using generic online instructions.
Diabetic Retinopathy
Rapid improvement in blood-glucose control can temporarily worsen diabetic retinopathy in some people. Current Zepbound safety information says patients with a history of diabetic retinopathy should be monitored for progression.
If you have diabetes and pre-existing retinal disease, make sure your clinician knows your eye history. New or changing vision symptoms should also be reported.
Serious Allergic Reactions
Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with Tirzepatide. In pooled Zepbound clinical studies, severe hypersensitivity reactions occurred in about 0.1% of Zepbound-treated participants and none receiving placebo.
Emergency symptoms can include:
- trouble breathing;
- rapid swelling of the face or throat;
- severe generalized allergic symptoms;
- or another rapidly progressing reaction.
These symptoms require urgent medical evaluation.
